PMID- 22234519
OWN - NLM
STAT- MEDLINE
DCOM- 20120820
LR  - 20181201
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 133
IP  - 1
DP  - 2012 May
TI  - Health-related quality of life, psychological distress, and adverse events in 
      postmenopausal women with breast cancer who receive tamoxifen, exemestane, or 
      anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of 
      Breast Cancer 04 (N-SAS BC 04).
PG  - 227-36
LID - 10.1007/s10549-011-1943-y [doi]
AB  - Health-related quality of life (HRQOL), symptoms of depression, and adverse 
      events (AEs) were compared between Japanese postmenopausal patients with 
      hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, 
      or anastrozole in an open-labeled, randomized, multicenter trial designated as 
      the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of 
      the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. During the first 
      year of treatment, HRQOL and symptoms of depression were analyzed using the 
      Functional Assessment of Cancer Therapy-Breast (FACT-B) and its Endocrine Symptom 
      Subscale (ES), and the Center for Epidemiologic Studies Depression Scale (CES-D), 
      respectively. In addition, predefined AEs were analyzed. A total of 166 eligible 
      patients were randomly assigned to receive adjuvant tamoxifen, exemestane, or 
      anastrozole. FACT-B scores increased after treatment began and remained 
      significantly higher in the tamoxifen group than in the exemestane group or 
      anastrozole group during the first year (P = 0.045). FACT-B scores were similar 
      in the exemestane group and anastrozole group. ES scores and CES-D scores were 
      similar in all treatment groups. Arthralgia and fatigue were less frequent, but 
      vaginal discharge was more frequent in the tamoxifen group than in the exemestane 
      group or anastrozole group. HRQOL was better in Japanese postmenopausal women 
      treated with tamoxifen than those treated with exemestane or anastrozole. HRQOL 
      and AEs were similar with exemestane and anastrozole. Given the results of the 
      TEAM trial, upfront use of tamoxifen followed by an aromatase inhibitor (AI) may 
      be an important option for adjuvant endocrine therapy in Japanese postmenopausal 
      women.
FAU - Takei, Hiroyuki
AU  - Takei H
AD  - Division of Breast Surgery, Saitama Cancer Center, 818 Komuro Ina, Kita-Adachi, 
      Saitama 362-0806, Japan. h-takei@cancer-c.pref.saitama.jp
FAU - Ohsumi, Shozo
AU  - Ohsumi S
FAU - Shimozuma, Kojiro
AU  - Shimozuma K
FAU - Takehara, Megumi
AU  - Takehara M
FAU - Suemasu, Kimito
AU  - Suemasu K
FAU - Ohashi, Yasuo
AU  - Ohashi Y
FAU - Hozumi, Yasuo
AU  - Hozumi Y
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20120111
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Androstadienes)
RN  - 0 (Nitriles)
RN  - 0 (Triazoles)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 2Z07MYW1AZ (Anastrozole)
RN  - NY22HMQ4BX (exemestane)
SB  - IM
MH  - Aged
MH  - Anastrozole
MH  - Androstadienes/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*adverse effects/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/psychology/surgery
MH  - Carcinoma/*drug therapy/psychology/surgery
MH  - Chemotherapy, Adjuvant
MH  - Depression/chemically induced
MH  - Female
MH  - Humans
MH  - Maintenance Chemotherapy
MH  - Middle Aged
MH  - Neoplasms, Hormone-Dependent/*drug therapy/psychology/surgery
MH  - Nitriles/administration & dosage
MH  - *Postmenopause
MH  - Quality of Life
MH  - Stress, Psychological/*chemically induced
MH  - Surveys and Questionnaires
MH  - Tamoxifen/administration & dosage
MH  - Treatment Outcome
MH  - Triazoles/administration & dosage
EDAT- 2012/01/12 06:00
MHDA- 2012/08/21 06:00
CRDT- 2012/01/12 06:00
PHST- 2011/06/19 00:00 [received]
PHST- 2011/12/23 00:00 [accepted]
PHST- 2012/01/12 06:00 [entrez]
PHST- 2012/01/12 06:00 [pubmed]
PHST- 2012/08/21 06:00 [medline]
AID - 10.1007/s10549-011-1943-y [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2012 May;133(1):227-36. doi: 10.1007/s10549-011-1943-y. 
      Epub 2012 Jan 11.